

GILEAD SCIENCES INC
Form 8-K
December 12, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

DATE OF REPORT:

December 12, 2002

(Date of earliest event reported)

GILEAD SCIENCES, INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State or other jurisdiction of
incorporation or organization)

0-19731

(Commission File Number)

94-3047598

(I.R.S. Employer
Identification No.)

333 LAKESIDE DRIVE, FOSTER CITY, CALIFORNIA

(Address of principal executive offices)

94404

(Zip Code)

(650) 574-3000

(Registrant's telephone number, including area code)

Item 5. OTHER EVENTS

On December 12, 2002, Gilead Sciences, Inc. announced that it intends to raise approximately \$300.0 million (\$345.0 million if the initial purchaser's over-allotment option is exercised in full) through an offering of five-year notes that are convertible into shares of Gilead common stock. A press release relating to the notes is attached hereto as Exhibit 99.1.

Item 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS

(c)

Edgar Filing: GILEAD SCIENCES INC - Form 8-K

Exhibits

99.1

Press Release dated December 12, 2002

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GILEAD SCIENCES, INC.

(registrant)

/s/ JOHN F. MILLIGAN

John F. Milligan
Senior Vice President and
Chief Financial Officer

Date: December 12, 2002

3

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release titled "Gilead to Raise \$300 Million from Offering of Convertible Notes" dated December 12, 2002.

4

QuickLinks

[SIGNATURES](#)

[EXHIBIT INDEX](#)